We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.
- Authors
Del Bano, Joanie; Florès-Florès, Rémy; Josselin, Emmanuelle; Goubard, Armelle; Ganier, Laetitia; Castellano, Rémy; Chames, Patrick; Baty, Daniel; Kerfelec, Brigitte
- Abstract
Triple negative breast cancers (TNBC) remain a major medical challenge due to poor prognosis and limited treatment options. Mesothelin is a glycosyl-phosphatidyl inositol-linked membrane protein with restricted normal expression and high level expression in a large proportion of TNBC, thus qualifying as an attractive target. Its overexpression in breast tumors has been recently correlated with a decreased disease-free survival and an increase of distant metastases. The objective of the study was to investigate the relevance of a bispecific antibody-based immunotherapy approach through mesothelin targeting and CD16 engagement using a Fab-like bispecific format (MesobsFab). Using two TNBC cell lines with different level of surface mesothelin and epithelial/mesenchymal phenotypes, we showed that, in vitro , MesobsFab promotes the recruitment and penetration of NK cells into tumor spheroids, induces potent dose-dependent cell-mediated cytotoxicity of mesothelin-positive tumor cells, cytokine secretion, and decreases cell invasiveness. MesobsFab was able to induce cytotoxicity in resting human peripheral blood mononuclear cells (PBMC), mainly through its NK cells-mediated antibody dependent cell cytotoxicity (ADCC) activity. In vivo , the anti-tumor effect of MesobsFab depends upon a threshold of MSLN density on target cells. Collectively our data support mesothelin as a relevant therapeutic target for the subset of TNBC that overexpresses mesothelin characterized by a low overall and disease-free survival as well as the potential of MesobsFab as antibody-based immunotherapeutics.
- Subjects
TRIPLE-negative breast cancer; CELL-mediated cytotoxicity; KILLER cells; BLOOD cells; THERAPEUTICS; BREAST cancer
- Publication
Frontiers in Immunology, 2019, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2019.01593